盈利预测、估值与评级 经营分析 上半年业绩下滑，Q2 环比改善：1）上半年由于下游降价压力向上 游传导，叠加公司产品结构变化，营收同比-0.83%；计提存货减 值 6922 万，信用减值 6433 万，使得归母净利润同比-20.3%；2） Q2 营收与归母净利润环比改善，归母净利润增速超过营收增速， 我们认为后续有望恢复高增长。 规模效益体现，Q2 毛利率环比提升：公司 25 年上半年毛利率为 44.7%（-6.1pct），净利率为 12.9%（-4.3pct）；25Q2 毛利率为 46.0% （同比-7.1pct，环比+3.5pct），净利率为 16.9%（同比-5.6pct， 环比+10.4pct）。后续随着公司的规模效应体现，利润率有望逐季 度改善。 积极备货生产，订单支撑后续成长：25Q2 末合同负债 3631 万元， 较 25Q1+19.23%，主要系销售产品预收货款增加；25Q2 末存货 24.69 亿元，较 25Q1+3.33%。结合合同负债和存货，我们认为公 司业绩后续有望逐季释放。 多项技术突破，新兴领域布局见成效：1）公司上半年研制出多款 高压抗辐射加固 MOSFET 产品；突破霍尔式接近 ...

Market Overview - The A-share market has shown a positive trend with the Shanghai Composite Index rising by 0.37% to 3516.83 points, the Shenzhen Component Index increasing by 1.43% to 10873.62 points, and the ChiNext Index up by 1.75% to 2269.33 points [1] - There is a noticeable increase in foreign investment interest in the Chinese market, with South Korean investors' cumulative trading volume in mainland and Hong Kong stocks exceeding $5.4 billion this year, making China the second-largest overseas investment destination for South Korean investors after the US [1][10] Sector Performance - The computing power, innovative pharmaceuticals, and military sectors have experienced significant gains, with the computing power sector leading the charge [2] - In the computing power sector, companies like Benq Intelligent, Shijia Photon, and Dekeli saw their stock prices rise over 10%, while Cambridge Technology and Changfei Fiber reached their daily limit [2][4] - The innovative pharmaceutical sector remains strong, with companies such as Weikang Pharmaceutical and Maiwei Bio achieving a 20% increase in stock price, and several others rising over 10% [5] Investment Sentiment - Citigroup has upgraded the ratings for Chinese and South Korean stock markets to "overweight," citing a constructive medium-term outlook despite macroeconomic volatility [9] - The report predicts that the Hang Seng Index will reach a target price of 25,000 points by the end of this year and 26,000 points by mid-next year, while the CSI 300 Index is expected to hit 4,200 points by year-end and 4,350 points by mid-next year [9] - In addition, the Invesco Global Sovereign Asset Management Research indicates a rebound in interest from international investment institutions towards the Chinese market, with a total asset management of approximately $27 trillion [12] Future Outlook - The military sector is also gaining traction, with companies like AVIC Shenfei and AVIC Aviation experiencing stock price surges [11] - The recent announcement by NVIDIA to resume supply of the H20 computing power chip for the Chinese market is expected to enhance domestic AI model training and inference capabilities, creating a positive feedback loop for demand [4] - The National Healthcare Security Administration's new policy for innovative drugs aims to balance accessibility and sustainability, indicating a strategic shift in healthcare policy that could benefit the pharmaceutical sector [6]

Summary of Fujida's Conference Call Company Overview - Fujida reported a 1% year-over-year decline in revenue for Q1 2025, with a net profit decrease of 6.68%, primarily due to insufficient demand for core military projects. However, orders increased by approximately 20% year-over-year, indicating potential future performance improvement. Civilian products accounted for 40% of revenue, while military defense and satellite-related businesses made up 60% [2][3][4]. Key Points Financial Performance - Q1 2025 revenue was 190 million yuan, with a net profit of 12.37 million yuan. The decline in revenue and profit was attributed to the delivery cycle impact from military project demand shortages [3][4]. - The company anticipates significant revenue growth in 2025, with an increase of at least 10% to 20%, although profit levels may not reach 2023 levels due to price reductions and sample giveaways in 2024 [4][32]. Profitability and Margins - Gross margin improvement was mainly due to increased output in the military sector, leading to economies of scale and reduced fixed cost amortization. Although military component margins are expected to decline in 2024, they are projected to stabilize in 2025 [2][6]. - The gross margin for the Q1 2025 remained stable, with the commercial satellite segment maintaining a margin of around 40% [2][31]. Orders and Inventory - Inventory increased from 123 million yuan in Q4 2024 to 139 million yuan in Q1 2025, reflecting pre-investment for projects following order increases [5]. - The average order-to-revenue conversion cycle is approximately three months, with noticeable improvements expected in Q2 2025 [9][11]. Research and Development - R&D investment accounted for about 8% of revenue, focusing on new military protection projects, which are crucial for long-term development [2][3][12]. - Despite a decline in military orders, R&D investment remained stable, with the proportion rising to around 11% due to overall revenue decline [12]. Market Dynamics - The commercial satellite market is stable, with Fujida securing a contract for 300 satellites from Samsung SDS, to be delivered by 2025. However, the launch schedule is lagging, with only one launch in Q1 2025 [16][31]. - The civilian market demand remains stable, with Fujida maintaining its bidding success for Huawei's 4G and 5G products, while also developing new high-end manufacturing instruments [20]. Future Plans and Strategies - Following the termination of a private placement, the company plans to secure funding through bank loans and other means to continue project development and expand production capacity for aerospace products [2][7][8]. - The company aims to expand its testing subsidiary's external third-party testing business, targeting electronic component manufacturers, with plans to grow this segment by 10% to 20% annually [4][38][39]. Challenges and Risks - The company faces challenges in meeting its five-year plan due to previous years' stagnation, making it difficult to achieve the original targets set for 2025 [14][32]. - There are rumors of changes in overseas market access policies, particularly in Europe, but the impact on Fujida's export business is expected to be minimal [21]. Additional Insights - The company is actively pursuing advancements in quantum computing and medical products, with ongoing collaborations and certifications aimed at replacing imported products [27][28]. - The cable business will continue to focus on military applications, despite exploring civilian products like high-speed copper cables [36]. This summary encapsulates the key insights and developments from Fujida's conference call, highlighting the company's current performance, market strategies, and future outlook.